Acumen Pharmaceuticals, Inc. (ABOS) vs Fortress Biotech, Inc. (FBIOP)

A side-by-side comparison of Acumen Pharmaceuticals, Inc. and Fortress Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ABOS vs FBIOP

growth of $100 · dividends reinvested · last 5y
ABOS -89.4% (-36.2%/yr)FBIOP +0.3% (+0.1%/yr)FBIOP compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020222023202420252026$11$100
ABOS FBIOP

ABOS vs FBIOP: by the numbers

  • •ABOS is the larger company ($154M vs $142M market cap).
  • •FBIOP is profitable (163.32% net margin) while ABOS runs a net loss (0.00%).

Metrics side by side

Valuation

MetricABOSFBIOP
P/E ratioN/A6.75
Forward P/EN/A7.10
P/S ratioN/A2.08
P/B ratio2.690.87
FCF yieldN/A88.32%

Profitability

MetricABOSFBIOP
Gross margin0.00%62.53%
Operating margin0.00%-111.00%
Net margin0.00%163.32%
ROE-183.44%68.12%
ROIC-118.67%-10.85%

Growth (annualized)

MetricABOSFBIOP
Revenue CAGR (5Y)N/A5.39%
Total return CAGR (5Y)-32.60%0.05%

Frequently asked

Is ABOS or FBIOP more profitable?
FBIOP runs the higher net margin — ABOS at 0.00% versus FBIOP at 163.32%.
How have ABOS and FBIOP total returns compared?
Over the past 5 years, ABOS delivered -32.60% and FBIOP delivered 0.05% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.